论文部分内容阅读
目的观察参麦注射液在初治晚期非小细胞肺癌化疗中的作用。方法治疗组采用参麦注射液50ml+5%葡萄糖500ml静脉滴注,1次/d,连用15d,在化疗开始前2d开始用药;对照组仅用化疗。所有病例均接受2个周期化疗。结果治疗组白细胞降低的例数及程度都明显优于对照组,两组有显著性差异(P<0.05)。治疗组与对照组在恶心呕吐反应方面无显著性差异(P>0.05),但治疗组重度呕吐比例稍低。结论参麦注射液在晚期非小细胞肺癌化疗时对骨髓抑制和胃肠道反应都有明显的预防和治疗作用,增强疗效,减轻化疗毒性,提高生存质量,提高化疗完成率。
Objective To observe the effect of Shenmai injection in the treatment of advanced non-small cell lung cancer. Methods The treatment group with Shenmai injection 50ml + 5% glucose 500ml intravenous infusion, 1 / d, once every 15d, before the start of chemotherapy 2d began to use drugs; the control group only with chemotherapy. All cases received 2 cycles of chemotherapy. Results The number and degree of leukopenia in the treatment group were significantly better than those in the control group, with significant difference between the two groups (P <0.05). There was no significant difference between the treatment group and the control group in the response to nausea and vomiting (P> 0.05), but the rate of severe vomiting in the treatment group was slightly lower. Conclusion Shenmai injection has obvious preventive and therapeutic effects on myelosuppression and gastrointestinal reaction in chemotherapy of advanced non-small cell lung cancer, enhance the curative effect, reduce the toxicity of chemotherapy, improve the quality of life, and improve the completion rate of chemotherapy.